Amgen to Establish Cutting-Edge Technology and Innovation Center in Hyderabad

American biopharmaceutical giant Amgen to open its India office in Hyderabad

Amgen, an American multinational biopharmaceutical company headquartered in Thousand Oaks, California, and one of the world's largest independent biotechnology companies, announced plans to open a new technology and innovation site in Hyderabad, Telangana. The site, known as Amgen India, will accelerate digital capabilities across the global organization to further advance Amgen's pipeline of medicines. The site can accommodate up to 3,000 people and will be operational in 2024. Chief Minister A. Revanth Reddy and Industries Minister Duddilla Sridhar Babu met Dr. David Reese and Mr. Som Chattopadhyay at Amgen's R&D site in San Francisco on Friday (August 09, 2024) to reaffirm their commitment to choose Hyderabad to open their next innovation site. Speaking after the meeting, IT and Industries Minister Sridhar Babu said he was thrilled to note that Amgen had chosen Hyderabad to establish Amgen India. This development is a powerful endorsement of the world-class life sciences ecosystem being cultivated in Telangana. He said the government was committed to partnering with Amgen to ensure their success here. "This marks the beginning of a promising, long-term collaboration, and we're excited about the healthier future we're building together." The Chief Minister said, "It is a great breakthrough and a matter of pride for us to have one of the world's largest biotech firms choose Hyderabad for its first development facilities in Telangana." "Amgen's new site in Hyderabad underscores the city's position as a hub for innovation and technology. We are proud to welcome a global trailblazer in the biotechnology industry. Amgen's unwavering mission to serve patients will be incredibly inspiring for the world-class technology talent seeking to make a meaningful impact on people around the world," he said. Roles offered at the site Hyderabad was selected for its world-class talent across medicine, life sciences and data sciences and the rapidly advancing field of Artificial Intelligence (AI). The site can accommodate up to 3,000 people and will be operational in Q4 2024, a note from the CMO officials said. The site will offer roles that strengthen key areas of Amgen's business, including AI, data science, life science and other additional global capabilities over time. "At a time when a quickly ageing global population needs more innovation, the convergence of biotechnology and technology is enabling Amgen to work with greater speed, confidence, and efficiency -- an incredibly exciting milestone for which we have been preparing for over a decade," said David M Reese, M.D., executive vice president and chief technology officer at Amgen. To lead Amgen's expanded presence in India, Som Chattopadhyay has been appointed national executive for India. Amgen has nearly 27,000 employees and has a presence in approximately 100 countries and regions worldwide. Read Comments

Amgen to Open new site in Hyderabad, INDIA

Amgen India Will Accelerate Innovation and Digital Capabilities Across Amgen's Global Organization Amgen (NASDAQ:AMGN) today announced plans to open a new technology and innovation site in Hyderabad, India. The site, known as Amgen India, will accelerate digital capabilities across the global organization to further advance Amgen's pipeline of medicines. Amgen India will be located in HITEC City, a suburb of Hyderabad, occupying six floors of the RMZ Spire Tower 110. The city of Hyderabad, located in the state of Telangana, was selected for its world-class talent across medicine, life sciences and data sciences and the rapidly advancing field of artificial intelligence (AI). The site can accommodate up to 3,000 people and will be operational in Q4 2024. "At a time when a quickly aging global population needs more innovation, the convergence of biotechnology and technology is enabling Amgen to work with greater speed, confidence, and efficiency -- an incredibly exciting milestone for which we have been preparing for over a decade," said David M. Reese, M.D., executive vice president and chief technology officer at Amgen. "Amgen has been a leader in biotechnology for over 40 years and establishing this new site in India, a country known for its world-class technology and life sciences talent, marks a significant step forward in our journey to deliver on our mission to serve patients." Amgen India will initially build and accelerate new technology solutions and digital capabilities at scale that will enhance efficiencies across the enterprise. The site will offer roles that strengthen key areas of Amgen's business, including AI, data science, life science and other additional global capabilities over time. To lead Amgen's expanded presence in India, Som Chattopadhyay has been appointed national executive for India. "Amgen's new site in Hyderabad underscores the city's position as a hub for innovation and technology," said Chief Minister Sri Anumula Revanth Reddy. "We are proud to welcome a global trailblazer of the biotechnology industry. Amgen's unwavering mission to serve patients will be incredibly inspiring for the world-class technology talent seeking to make a meaningful impact on people around the world." Amgen has nearly 27,000 employees and has a presence in approximately 100 countries and regions worldwide, including India. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

Amgen to open new tech and innovation center in Hyderabad by end of 2024 | Hyderabad News - Times of India

HYDERABAD: US-based biopharma giant Amgen is setting up its new technology and innovation centre in Hyderabad. The new facility -- Amgen India - is slated to become operational in the fourth quarter of this year and will have a capacity to accommodate up to 3,000 employees. Amgen said the new tech and innovation centre is aimed at accelerating digital capabilities across the global organisation to advance Amgen's pipeline of medicines. "Amgen India will initially build and accelerate new technology solutions and digital capabilities at scale that will enhance efficiencies across the enterprise," the company said. The site will offer roles that strengthen key areas of Amgen's business, including AI, data science, life science and other additional global capabilities over time, it added. The company has already appointed Som Chattopadhyay as national executive for India as part of Amgen's expanded presence in India. The company said it had zeroed in on Hyderabad, where it has acquired six floors in the RMZ Spire project in the heart of Hyderabad's IT district, because of its world-class talent across medicine, life sciences and data sciences as well as artificial intelligence (AI). Telangana chief minister Anumula Revanth Reddy said Amgen's new site in Hyderabad underscores the city's position as a global hub for innovation and technology. "It is a matter of pride for us to welcome one of the world's largest biotech firms to Hyderabad. This reinforces our city's position as a global leader in innovation and technology," CM announced on social media platform X. "Amgen's choice to establish its first development facilities in Telangana is a powerful endorsement of our world-class life sciences ecosystem. We are committed to a long-term partnership with Amgen to ensure their success and contribute to a healthier future. Together with Amgen, we are building a future where cutting-edge biotechnology meets top-notch talent in #Telangana! #AmgenIndia #Biotechnology #InvestInTelangana," he said. Amgen's executive vice president and chief technology officer (CTO) David M Reese said: "Establishing this new site in India, known for its world-class technology and life sciences talent, marks a significant step forward in our journey to deliver on our mission to serve patients." "At a time when a quickly aging global population needs more innovation, the convergence of biotechnology and technology is enabling Amgen to work with greater speed, confidence, and efficiency," he added. Amgen, which clocked revenues of over US$28 billion in 2023, has around 27,000 employees with a presence in about 100 countries and regions worldwide, including India.

Amgen is Launching Biotechnology and AI Hub in Hyderabad

Som Chattopadhyay has been appointed as the national executive for India, leading the expanded operations. Amgen, a company focusing on biotechnology, discovering, developing, manufacturing, and delivering innovative medicines, has announced plans to establish a new technology and innovation site in Hyderabad, India, to accelerate digital capabilities across its global operations. The site, named Amgen India, will support the advancement of Amgen's drug pipeline and is expected to be operational by Q4 2024. Located in HITEC City, Hyderabad, the facility will span six floors of the RMZ Spire Tower 110, accommodating up to 3,000 employees. Hyderabad was selected for its strong talent pool in medicine, life sciences, data sciences, and AI. David M. Reese, M.D., executive vice president and CTO at Amgen, highlighted the significance of the new site, stating, "At a time when a quickly aging global population needs more innovation, the convergence of biotechnology and technology is enabling Amgen to work with greater speed, confidence, and efficiency -- an incredibly exciting milestone for which we have been preparing for over a decade." Amgen India will focus on developing new technology solutions and digital capabilities to enhance operational efficiencies across the enterprise. The site will create roles in AI, data science, life science, and other global capabilities as the operation expands. Som Chattopadhyay has been appointed as the national executive for India, leading the expanded operations. Telangana Chief Minister Sri Anumula Revanth Reddy welcomed the development, stating, "We are proud to welcome a global trailblazer of the biotechnology industry. Amgen's unwavering mission to serve patients will be incredibly inspiring for the world-class technology talent seeking to make a meaningful impact on people around the world." Amgen, with nearly 27,000 employees, has a global presence in approximately 100 countries and regions, including India. With more than 40 years in the industry, Amgen continues to advance a broad pipeline of treatments for cancer, heart disease, osteoporosis, inflammatory diseases, and rare conditions.

Biotech giant Amgen plans to open to technology & innovation centre in Hyderabad

US biotech giant Amgen on Friday announced its plans to open a new technology and innovation site in Hyderabad, India. The site, to be known as Amgen, will be located in HITEC City, a suburb of Hyderabad, occupying six floors of the RMZ Spire Tower, with a potential to accommodate up to 3,000 people. The site will be operational in Q4 2024. Amgen India will initially build and accelerate new technology solutions and digital capabilities at scale that will enhance efficiencies across the enterprise. The site will offer roles that strengthen key areas of Amgen's business, including artificial intelligence (AI), data science, life science and other additional global capabilities over time. Som Chattopadhyay has been appointed as national executive to lead Amgen's expanded presence in India. The California based Amgen with revenues of $28.2 billion in 2023, is one of the world's leading biotech companies with nearly 27,000 employees and has a presence in around 100 countries and regions worldwide, including India. "At a time when a quickly aging global population needs more innovation, the convergence of biotechnology and technology is enabling Amgen to work with greater speed, confidence, and efficiency -- an incredibly exciting milestone for which we have been preparing for over a decade," said David M. Reese, executive vice president and chief technology officer at Amgen. "Amgen has been a leader in biotechnology for over 40 years and establishing this new site in India, a country known for its world-class technology and life sciences talent, marks a significant step forward in our journey to deliver on our mission to serve patients," Reese added. "Amgen's new site in Hyderabad underscores the city's position as a hub for innovation and technology," Chief Minister Anumula Revanth Reddy said welcoming the investment. Multinational pharma and medtech companies are setting up GCCs in India to take advantage of talent, especially in the technology domain to support their global operations as well as building AI tools to optimise manufacturing operations, finding drug discovery targets, simulating clinical trials among others. In recent months Sanofi has announced investment of Rs 3600 crore on expansion of its GCC in Hyderabad, British-Swedish drugmaker AstraZeneca said it plans to invest Rs 250 crore to grow its Global Innovation and Technology Centre in Chennai, bringing some 1,300 highly skilled roles by 2025. Novartis was an early entrant to India, the Swiss pharma company employs more than 8,100 associates in India, of which lion share work at its GCC in Hyderabad. Bristol Myers Squibb (BMS), Bayer, Merck, Novo Nordisk, Medtronic, Siemens Healthineers, GE Healthcare, among others have established GCCs in India.